摘要
Abstract
Objective: To observe the clinical efficacy of Shengxuening tablets to improve the law to maintain iron metabolism in hemodialysis patients with renal anemia and erythropoietin and its synergistic effect. Methods:60 cases uremic patients with renal anemia selected as the research object, randomly divided into Shengxuening group and succinic acid ferrous group, 30 cases in each group. The patients of shengxuen-ing group were given oral Shengxuening tablets, and oral ferrous succinate group was given Ferrous Succinate Tablets. In accordance with the guidelines, the patients of 2 groups were given the recommended dose individ-ualized combination of erythropoietin treatment. After 16-weeks treatment, the clinical curative effect of the patients of 2 groups were observed and the changes of hemoglobin, hematocrit, serum ferritin and transferrin saturation were recorded before and after treatment in 2 groups. Meanwhile, the adverse reactions in the 2 groups were monitored. Results: After 16 weeks of treatment, the hemoglobin, hematocrit, serum ferritin, transferrin saturation of the 2 groups were increased compared with before treatment, the difference was statis-tically significant ( P < 0.05) . However, after treatment, the hemoglobin, hematocrit, serum ferritin, trans-ferrin saturation of Shengxuening group was significantly higher than that of ferrous succinate group, the differ-ence was statistically significant ( P < 0.05) . Compared with ferrous succinate group, Shengxuening group of adverse reaction is less. Conclusion: Compared with ferrous succinate group, Shengxuening can effectively supplement renal anemia in patients with uremia for iron, and less adverse reactions of blood safety.关键词
生血宁/肾性贫血/血液透析Key words
Shengxuening/Renal anemia/Hemodialysis
